If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
DERMATOLOGY
EMJ Dermatol. 2019 Suppl 2 • europeanmedical-journal.com
INSIDE
Dimethyl Fumarate in
Psoriasis Therapy
Dimethyl Fumarate in Psoriasis Therapy
This meeting took place on 12th October 2018, as part of
the 2nd European Workshop on Skin Immune Mediated
Inflammatory Diseases (SIMID) in Verona, Italy
Speakers: Peter Weisenseel
Dermatologikum, Hamburg, Germany
Disclosure: Dr Weisenseel is a speaker, investigator, and advisor for Almirall, Biogen Idec,
and other pharmaceutical companies that produce or distribute drugs for psoriasis,
including Abbvie, BMS, Celgene, LeoPharma, Janssen, Eli Lilly, Novartis, Medac,
Dexcel, Böhringer, Pfizer, and MSD.<
DERMATOLOGY EMJ Dermatol. 2019 Suppl 2 • european
Dimethyl Fumarate in Psoriasis Therapy This meet
Cambridge, Massachusetts, USA), for multiple
Patients achieving PASI 75 (%) 45 40 35 30
term therapy.19 Recommendations for avoiding flush
References 1. Das deutsche Psoriasis-Registe